Diablo Clinical Research, Inc ( Site 0042)(4.7 mi away)Contact
+105 other location
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the
9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45 years of age. The primary
hypothesis tested in this study is that administration of a 3-dose regimen of 9vHPV vaccine
will reduce the incidence of HPV 16/18/31/33/45/52/58-related oral persistent infection (6
months or longer) compared with placebo.
Placebo (Saline for Injection)
Clinical Study Identifier
Merck Sharp & Dohme Corp.
Last Modified on
27 November 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.